GLP-1 compounding is moving from shortage-era access to enforcement-era scrutiny.
The tracker prioritizes FDA shortage notices, 503A and 503B policy, warning letters, and OIG oversight signals.
Peptide Tracker
Unvarnished peptide updates, ready for editorial review.
A source-first queue for FDA actions, GLP-1 compounding policy, warning letters, anti-doping rules, pharmacy oversight, and trade-body responses. These are not rewritten press releases; every item starts with the source that should anchor the article.
14active source items
5primary-source channels
6ready to paraphrase
Injectable quality and dosing-error notices belong on safety pages, not buried in footnotes.
When FDA flags dosing errors, sterility, or CGMP concerns, the relevant profile and access pages should get revised.
Peptide-hormone claims need WADA context before any performance framing.
WADA is treated as the source of record for anti-doping status, with clinical evidence handled separately.
Brief Archive
Search Medriva peptide briefs by date or topic
Weekday briefs are collected here after publication. Search by month, date, drug, regulator, or source theme, then open the archived brief directly.
4 briefsLatest 2026-06-05
2026-06-05June 2026 Peptide News ArchiveJune opened with peptide policy, GLP-1 compounding, Retatrutide pipeline questions, and safety context moving together.2026-06-05May 2026 Peptide News Archive: Evidence Guide (2026)May brought GLP-1 access, compounding policy, telehealth marketing, warning-letter activity, and next-generation metabolic peptides into the same frame.2026-06-05TB-500 Is Just Thymosin β-4 Guide (2026)2026-06-05The Truth About GLP-1 and Alcohol: Guide (2026)
Source Queue
Monitored source queue
Each card links to the originating source and labels the regulatory, safety, clinical, or industry context that may need a future Medriva update.
2026-06-06FDA GLP-1 compounding updates
RegulatorSource reviewed
CDER Update
The U.S. Food and Drug Administration has determined the shortage of tirzepatide injection, a glucagon-like peptide 1 (GLP-1) medication, has been resolved. Tirzepatide injection has been in shortage since 2022 due to increased demand.
Why it matters: This primary source can affect peptide, GLP-1, safety, regulatory, or access coverage.
Article angle: Use this source to update the tracker or an existing canonical Medriva page when the change is material.
2026-06-06FDA warning letters
RegulatorSource reviewed
Warning Letters
Main FDA Warning Letter Page
Why it matters: This primary source can affect peptide, GLP-1, safety, regulatory, or access coverage.
Article angle: Use this source to update the tracker or an existing canonical Medriva page when the change is material.
2026-06-06FDA human drug compounding
RegulatorSource reviewed
Compounding: Inspections, Recalls, and other Actions
Inspections, recalls and other actions of compounders under section 503A and outsourcing facilities under section 503B
Why it matters: This primary source can affect peptide, GLP-1, safety, regulatory, or access coverage.
Article angle: Use this source to update the tracker or an existing canonical Medriva page when the change is material.
2026-06-06HHS Office of Inspector General
Federal oversightSource reviewed
Browse Work Plan Projects
Browse Work Plan Projects | Office of Inspector General | Government Oversight | U.S. Department of Health and Human Services Skip to main content An official website of the United States government Here’s how you know Here’s how you know Official websites use .gov A .gov website belongs to an official government organization in the United States. Secure .go
Why it matters: This primary source can affect peptide, GLP-1, safety, regulatory, or access coverage.
Article angle: Use this source to update the tracker or an existing canonical Medriva page when the change is material.
2026-06-06WADA prohibited list
Sports regulatorSource reviewed
WADA prohibited list
Peptide hormones, growth factors, mimetics, and athlete-facing restrictions.
Why it matters: This primary source can affect peptide, GLP-1, safety, regulatory, or access coverage.
Article angle: Use this source to update the tracker or an existing canonical Medriva page when the change is material.
2026-06-06Alliance for Pharmacy Compounding
Trade bodySource reviewed
APC News Feed
News and more from the Alliance for Pharmacy Compounding
Why it matters: This industry context can affect peptide, GLP-1, safety, regulatory, or access coverage.
Article angle: Use this source to update the tracker or an existing canonical Medriva page when the change is material.
2026-04-30FDA
Proposed ruleReady to paraphrase
FDA proposes excluding semaglutide, tirzepatide, and liraglutide from the 503B Bulks List.
The proposal would keep 503B outsourcing facilities from compounding these GLP-1 active ingredients from bulk drug substances unless another legal pathway applies.
Why it matters: This is one of the clearest policy signals on where FDA wants the post-shortage GLP-1 compounding market to land.
Article angle: Explain what 503B facilities can and cannot do after the shortage-era enforcement discretion ends.
2026-04-15HHS OIG
Oversight work planWatch
Federal watchdog adds FDA oversight of compounded GLP-1 drugs to its work plan.
OIG flagged a review of FDA oversight for compounded GLP-1 drugs, with a final report expected later in the decade.
Why it matters: A watchdog review raises the odds of sharper documentation, inspection, and enforcement expectations around compounded GLP-1s.
Article angle: Track what OIG is asking, what FDA already controls, and what consumers should watch while the review is open.
2026-04-07FDA
Warning letterReady to paraphrase
FDA warning letter to ProRx cites outsourcing-facility quality and sterility concerns.
FDA identified CGMP and sterility-related concerns at a 503B outsourcing facility and tied the review to compounded drug products including GLP-1 preparations.
Why it matters: Quality-system failures are not abstract when a compounded injectable is involved; this belongs in every access and safety update.
Article angle: Turn the warning letter into a plain-English quality checklist for readers evaluating compounded injectables.
2026-03-03FDA
Enforcement noticeReady to paraphrase
FDA warns 30 telehealth companies over marketing of compounded GLP-1 drugs.
FDA said companies were making illegal marketing claims around compounded GLP-1 products and failing to communicate required risk context.
Why it matters: This separates evidence-led GLP-1 education from commercial copy that implies compounded products are FDA-approved substitutes.
Article angle: Create a reader guide on marketing claims that should trigger skepticism before buying or booking a consult.
2026-02-06FDA
Policy clarificationReady to paraphrase
FDA clarifies compounder policies as the national GLP-1 supply stabilizes.
FDA outlined enforcement-discretion end dates after resolving tirzepatide and semaglutide shortage status, with different windows for 503A and 503B compounders.
Why it matters: Many access and cost pages still repeat shortage-era assumptions. This is the source that resets that timeline.
Article angle: Publish a timeline showing when shortage-based compounding discretion ended and what exceptions remain.
2025-07-31FDA
Safety updateReady to paraphrase
FDA updates concerns about unapproved GLP-1 drugs used for weight loss.
FDA highlights dosing errors, adverse-event reports, and risks from unapproved GLP-1 products, including non-commercial active ingredients promoted online.
Why it matters: This is the safety anchor for pages on compounded semaglutide, tirzepatide, retatrutide claims, and copycat GLP-1 marketing.
Article angle: Build a safety explainer that distinguishes FDA-approved GLP-1 drugs from unapproved and copycat products.
2025-09-25WADA
Prohibited listReady to paraphrase
WADA publishes the 2026 Prohibited List covering peptide hormones and growth factors.
The prohibited list is the athlete-facing source for peptide hormones, growth factors, related substances, and mimetics.
Why it matters: Sports and recovery pages need a clear line between medical-use discussion and substances that can create anti-doping exposure.
Article angle: Translate the WADA peptide-hormone categories into a practical athlete safety page without giving evasion advice.
2026-02-06Alliance for Pharmacy Compounding
Trade-body responseContext only
Compounding trade body responds to FDA's GLP-1 API restriction plan.
The trade-body response is useful context for industry arguments, but it should be treated separately from FDA policy.
Why it matters: Readers deserve to see both the regulator's position and the industry's response without confusing them as equally authoritative.
Article angle: Create a source-comparison piece: what FDA says, what compounders say, and where patients still need clinician guidance.
Monitored Sources
Regulators first, trade bodies labeled clearly
Primary-source channels carry the evidentiary weight. Trade-body pages are useful for industry response, but the tracker keeps that context visibly separate.
Regulator · Primary source
FDA GLP-1 compounding updates
Shortage status, enforcement policy, 503A and 503B transition windows.
Regulator · Primary source
FDA warning letters
Vendor, telehealth, compounding, labeling, quality, and sterility enforcement.
Regulator · Primary source
FDA human drug compounding
503A, 503B, bulk-substance, and outsourcing-facility policy.
Federal oversight · Primary source
HHS Office of Inspector General
Oversight audits, work-plan items, and fraud-risk reviews.
Sports regulator · Primary source
WADA prohibited list
Peptide hormones, growth factors, mimetics, and athlete-facing restrictions.
Trade body · Industry context
Alliance for Pharmacy Compounding
Compounding-industry response to FDA, OIG, and state-board actions.
Trade body · Industry context
Outsourcing Facilities Association
503B outsourcing-facility litigation, policy response, and operational updates.
Pharmacy oversight · Verification layer
NABP
Digital pharmacy safety, state-board signals, and consumer-risk warnings.
